SlideShare una empresa de Scribd logo
1 de 37
Intellectual Property Protection for Drugs, Biologics and Medical Devices in the U.S. and European Union Comparative EU and U.S. Science, Law and Policy in the Regulation of Pharmaceuticals and Medical Technology Chuck Schmal Patent & Trademark Attorney [email_address]
Patenting Medical Inventions ,[object Object],[object Object]
Patenting Medical Inventions in the U.S. ,[object Object],[object Object]
Patenting Medical Inventions in the EU ,[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Patenting a  Surgical Method  in the EU ,[object Object],[object Object],[object Object]
Patenting a  Surgical Method  in the EU ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
Patenting a  Drug Treatment  in the EU ,[object Object],[object Object],[object Object]
Patenting a  Drug Treatment  in the EU ,[object Object],[object Object],[object Object]
Patenting a  Drug Treatment  in the EU ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Patenting a  Diagnostic Method  in the U.S. ,[object Object],[object Object],[object Object],[object Object]
Patenting a  Diagnostic Method  in the EU ,[object Object],[object Object],[object Object]
Patenting a  Diagnostic Method  in the EU ,[object Object],[object Object],[object Object],[object Object]
Patenting a  New Drug  in the U.S. ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Patenting a  New Drug  in the EU ,[object Object],[object Object]
Patenting a  New Drug  in the EU ,[object Object],[object Object],[object Object],[object Object]
Patenting a  New Drug  in the EU ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Patenting a  New Medical Device  in the U.S. ,[object Object],[object Object],[object Object],[object Object],[object Object]
Patenting a  New Medical Device  in the EU ,[object Object],[object Object],[object Object],[object Object],[object Object]
Patenting a  New Medical Device  in the EU ,[object Object],[object Object]
Comparative Protection Real World Example: Method & Apparatus for Creating Abdominal Visceral Anastomoses
Comparative Protection Real World Example: Method & Apparatus for Creating Abdominal Visceral Anastomoses
Comparative Protection Real World Example: Method & Apparatus for Creating Abdominal Visceral Anastomoses ,[object Object],[object Object]
Comparative Protection Real World Example: Method & Apparatus for Creating Abdominal Visceral Anastomoses ,[object Object],[object Object],[object Object],[object Object],[object Object]
Comparative Protection Real World Example: Method & Apparatus for Creating Abdominal Visceral Anastomoses ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Comparative Protection Real World Example: Method & Apparatus for Creating Abdominal Visceral Anastomoses ,[object Object],[object Object],[object Object]
Comparative Protection Real World Example: Method & Apparatus for Creating Abdominal Visceral Anastomoses ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Comparative Protection Real World Example: Method & Apparatus for Creating Abdominal Visceral Anastomoses ,[object Object],[object Object],[object Object],[object Object],[object Object]
Comparative Protection Real World Example: Method & Apparatus for Creating Abdominal Visceral Anastomoses ,[object Object],[object Object],[object Object],[object Object]
Patenting  Biotechnology  Inventions in EU ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Patenting  Biotechnology  Inventions in EU ,[object Object],[object Object],[object Object],[object Object]
Patenting  DNA and Protein Sequences  in US/EU ,[object Object],[object Object],[object Object],[object Object]
Specific Exceptions to Patentability in the EU ,[object Object],[object Object]
Specific Exceptions to Patentability in the EU ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Summary ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Más contenido relacionado

Similar a IP Protection-for-drugs-biologics-and-medical-devices-useu-ip-comparison

CELEX 52014DC0188 EN TXT_Raport en.pdf
CELEX 52014DC0188 EN TXT_Raport en.pdfCELEX 52014DC0188 EN TXT_Raport en.pdf
CELEX 52014DC0188 EN TXT_Raport en.pdfssuser7f7ec8
 
CELEX 52014DC0188 EN TXT_Raport en.pdf
CELEX 52014DC0188 EN TXT_Raport en.pdfCELEX 52014DC0188 EN TXT_Raport en.pdf
CELEX 52014DC0188 EN TXT_Raport en.pdfssuser7f7ec8
 
Best Practices: IP Strategies for Diagnostics
Best Practices: IP Strategies for DiagnosticsBest Practices: IP Strategies for Diagnostics
Best Practices: IP Strategies for DiagnosticsMaRS Discovery District
 
Brexit implications for UK pharmaceuticals legislation
Brexit implications for UK pharmaceuticals legislationBrexit implications for UK pharmaceuticals legislation
Brexit implications for UK pharmaceuticals legislationAndrew Hollingsworth
 
European medicines agency
European medicines agencyEuropean medicines agency
European medicines agencyVicky Vignesh
 
P A T I E N T v P F I Z E R
P A T I E N T v P F I Z E RP A T I E N T v P F I Z E R
P A T I E N T v P F I Z E RGeorgi Daskalov
 
Indian Patent act, 20 feb
Indian Patent act, 20 febIndian Patent act, 20 feb
Indian Patent act, 20 febjyothics
 
Vitafoods eu clinical trials regulation
Vitafoods   eu clinical trials regulationVitafoods   eu clinical trials regulation
Vitafoods eu clinical trials regulationAxon Lawyers
 
SPCs as Targets for Litigation: C5 Presentation 18 February 2009
SPCs as Targets for Litigation: C5 Presentation 18 February 2009SPCs as Targets for Litigation: C5 Presentation 18 February 2009
SPCs as Targets for Litigation: C5 Presentation 18 February 2009Dr Duncan Curley
 
PHARMACOVIGILANCE (1)_f3cbd0ce-d8ba-4482-a714-a2a728fb48ad.pptx
PHARMACOVIGILANCE (1)_f3cbd0ce-d8ba-4482-a714-a2a728fb48ad.pptxPHARMACOVIGILANCE (1)_f3cbd0ce-d8ba-4482-a714-a2a728fb48ad.pptx
PHARMACOVIGILANCE (1)_f3cbd0ce-d8ba-4482-a714-a2a728fb48ad.pptxVennaswapna
 
Turkiyede klinik arastirma 2015 ing
Turkiyede klinik arastirma 2015 ingTurkiyede klinik arastirma 2015 ing
Turkiyede klinik arastirma 2015 ingtyfngnc
 
I.s. forrester, a. dawes, parallel trade in medicines
I.s. forrester, a. dawes, parallel trade in medicinesI.s. forrester, a. dawes, parallel trade in medicines
I.s. forrester, a. dawes, parallel trade in medicinesMichal
 
Insights: EU Healthcare Policy March 2013
Insights: EU Healthcare Policy March 2013Insights: EU Healthcare Policy March 2013
Insights: EU Healthcare Policy March 2013MSL
 
Investigation of medicinal product dossier (IMPD)
Investigation of medicinal product dossier (IMPD)Investigation of medicinal product dossier (IMPD)
Investigation of medicinal product dossier (IMPD)Himal Barakoti
 
Methods of Medical Treatment Claims Issues in Canada US and Europe
Methods of Medical Treatment Claims Issues in Canada US and EuropeMethods of Medical Treatment Claims Issues in Canada US and Europe
Methods of Medical Treatment Claims Issues in Canada US and EuropeThis account is closed
 

Similar a IP Protection-for-drugs-biologics-and-medical-devices-useu-ip-comparison (20)

CELEX 52014DC0188 EN TXT_Raport en.pdf
CELEX 52014DC0188 EN TXT_Raport en.pdfCELEX 52014DC0188 EN TXT_Raport en.pdf
CELEX 52014DC0188 EN TXT_Raport en.pdf
 
CELEX 52014DC0188 EN TXT_Raport en.pdf
CELEX 52014DC0188 EN TXT_Raport en.pdfCELEX 52014DC0188 EN TXT_Raport en.pdf
CELEX 52014DC0188 EN TXT_Raport en.pdf
 
Best Practices: IP Strategies for Diagnostics
Best Practices: IP Strategies for DiagnosticsBest Practices: IP Strategies for Diagnostics
Best Practices: IP Strategies for Diagnostics
 
Brexit implications for UK pharmaceuticals legislation
Brexit implications for UK pharmaceuticals legislationBrexit implications for UK pharmaceuticals legislation
Brexit implications for UK pharmaceuticals legislation
 
Ipr final
Ipr finalIpr final
Ipr final
 
European medicines agency
European medicines agencyEuropean medicines agency
European medicines agency
 
2535 may 2013
2535 may 20132535 may 2013
2535 may 2013
 
P A T I E N T v P F I Z E R
P A T I E N T v P F I Z E RP A T I E N T v P F I Z E R
P A T I E N T v P F I Z E R
 
Indian Patent act, 20 feb
Indian Patent act, 20 febIndian Patent act, 20 feb
Indian Patent act, 20 feb
 
Vitafoods eu clinical trials regulation
Vitafoods   eu clinical trials regulationVitafoods   eu clinical trials regulation
Vitafoods eu clinical trials regulation
 
SPCs as Targets for Litigation: C5 Presentation 18 February 2009
SPCs as Targets for Litigation: C5 Presentation 18 February 2009SPCs as Targets for Litigation: C5 Presentation 18 February 2009
SPCs as Targets for Litigation: C5 Presentation 18 February 2009
 
EU competition law and patent settlements
EU competition law and patent settlementsEU competition law and patent settlements
EU competition law and patent settlements
 
PHARMACOVIGILANCE (1)_f3cbd0ce-d8ba-4482-a714-a2a728fb48ad.pptx
PHARMACOVIGILANCE (1)_f3cbd0ce-d8ba-4482-a714-a2a728fb48ad.pptxPHARMACOVIGILANCE (1)_f3cbd0ce-d8ba-4482-a714-a2a728fb48ad.pptx
PHARMACOVIGILANCE (1)_f3cbd0ce-d8ba-4482-a714-a2a728fb48ad.pptx
 
Turkiyede klinik arastirma 2015 ing
Turkiyede klinik arastirma 2015 ingTurkiyede klinik arastirma 2015 ing
Turkiyede klinik arastirma 2015 ing
 
I.s. forrester, a. dawes, parallel trade in medicines
I.s. forrester, a. dawes, parallel trade in medicinesI.s. forrester, a. dawes, parallel trade in medicines
I.s. forrester, a. dawes, parallel trade in medicines
 
Acs presentation
Acs presentationAcs presentation
Acs presentation
 
Insights: EU Healthcare Policy March 2013
Insights: EU Healthcare Policy March 2013Insights: EU Healthcare Policy March 2013
Insights: EU Healthcare Policy March 2013
 
ICH GCP guidelines
ICH  GCP  guidelinesICH  GCP  guidelines
ICH GCP guidelines
 
Investigation of medicinal product dossier (IMPD)
Investigation of medicinal product dossier (IMPD)Investigation of medicinal product dossier (IMPD)
Investigation of medicinal product dossier (IMPD)
 
Methods of Medical Treatment Claims Issues in Canada US and Europe
Methods of Medical Treatment Claims Issues in Canada US and EuropeMethods of Medical Treatment Claims Issues in Canada US and Europe
Methods of Medical Treatment Claims Issues in Canada US and Europe
 

Más de Woodard, Emhardt, Henry, Reeves & Wagner, LLP

Más de Woodard, Emhardt, Henry, Reeves & Wagner, LLP (20)

2017 08-patent prosecution lunch
2017 08-patent prosecution lunch2017 08-patent prosecution lunch
2017 08-patent prosecution lunch
 
Recent Developments in US Trademark Law
Recent Developments in US Trademark LawRecent Developments in US Trademark Law
Recent Developments in US Trademark Law
 
2017 March Patent Prosecution Lunch
2017 March Patent Prosecution Lunch2017 March Patent Prosecution Lunch
2017 March Patent Prosecution Lunch
 
February 2017 Patent Prosecution Lunch
February 2017 Patent Prosecution LunchFebruary 2017 Patent Prosecution Lunch
February 2017 Patent Prosecution Lunch
 
Alice Corp Update 2016 Cases
Alice Corp Update 2016 CasesAlice Corp Update 2016 Cases
Alice Corp Update 2016 Cases
 
2017 January Patent Prosecution Lunch
2017 January Patent Prosecution Lunch2017 January Patent Prosecution Lunch
2017 January Patent Prosecution Lunch
 
2016 September Patent Prosecution Lunch
2016 September Patent Prosecution Lunch2016 September Patent Prosecution Lunch
2016 September Patent Prosecution Lunch
 
2016 August Patent Prosecution Lunch
2016 August Patent Prosecution Lunch2016 August Patent Prosecution Lunch
2016 August Patent Prosecution Lunch
 
Review of Recent IP Supreme Court Cases
Review of Recent IP Supreme Court CasesReview of Recent IP Supreme Court Cases
Review of Recent IP Supreme Court Cases
 
Defend Trade Secrets Act of 2016
Defend Trade Secrets Act of 2016Defend Trade Secrets Act of 2016
Defend Trade Secrets Act of 2016
 
July 2016 Trademark Prosecution Lunch Update
July 2016 Trademark Prosecution Lunch UpdateJuly 2016 Trademark Prosecution Lunch Update
July 2016 Trademark Prosecution Lunch Update
 
2016 07-Patent Prosecution Lunch
2016 07-Patent Prosecution Lunch2016 07-Patent Prosecution Lunch
2016 07-Patent Prosecution Lunch
 
Federal Rules Update
Federal Rules UpdateFederal Rules Update
Federal Rules Update
 
January 2016 Trademark Prosecution Lunch
January 2016  Trademark Prosecution LunchJanuary 2016  Trademark Prosecution Lunch
January 2016 Trademark Prosecution Lunch
 
In re tam presentation
In re tam presentationIn re tam presentation
In re tam presentation
 
January 2016 Patent Prosecution Lunch
January 2016 Patent Prosecution LunchJanuary 2016 Patent Prosecution Lunch
January 2016 Patent Prosecution Lunch
 
International Copyright Protection Primer
International Copyright Protection PrimerInternational Copyright Protection Primer
International Copyright Protection Primer
 
2015 October Patent Prosecution Lunch
2015 October Patent Prosecution Lunch 2015 October Patent Prosecution Lunch
2015 October Patent Prosecution Lunch
 
CLE - Introduction to IP Law
CLE - Introduction to IP LawCLE - Introduction to IP Law
CLE - Introduction to IP Law
 
August 2015 Patent Prosecution Lunch
August 2015 Patent Prosecution LunchAugust 2015 Patent Prosecution Lunch
August 2015 Patent Prosecution Lunch
 

IP Protection-for-drugs-biologics-and-medical-devices-useu-ip-comparison

  • 1. Intellectual Property Protection for Drugs, Biologics and Medical Devices in the U.S. and European Union Comparative EU and U.S. Science, Law and Policy in the Regulation of Pharmaceuticals and Medical Technology Chuck Schmal Patent & Trademark Attorney [email_address]
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23. Comparative Protection Real World Example: Method & Apparatus for Creating Abdominal Visceral Anastomoses
  • 24. Comparative Protection Real World Example: Method & Apparatus for Creating Abdominal Visceral Anastomoses
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.